Cellectar Biosciences Inc (FRA:NV40)

Q3 2025 Cellectar Biosciences Inc Earnings Call Transcript

Nov 13, 2025 / 01:30 PM GMT

Release Date Price: €0.2515

Transcript 8-K10-Q

Key Points

Positve

Cellectar Biosciences Inc (CLRB) has made significant advancements in its global regulatory strategy for iapofecine I-131, receiving confirmation of eligibility to file for conditional marketing approval in the EU.
The company has strengthened its balance sheet by raising approximately $12.7 million in recent financings, ensuring adequate funding for operations into the third quarter of 2026.
Iapofecine I-131 has been granted breakthrough designation for Waldenstrom's macroglobulinemia by the FDA, with a high probability of accelerated approval.
Cellectar Biosciences Inc (CLRB) is actively pursuing strategic partnerships to expedite the commercialization of iapofecine I-131 and secure non-dilutive capital.
The company has initiated a phase 1B study of CLR 125 for triple negative breast cancer, showcasing progress in its next-generation radiopharmaceutical pipeline.

Negative

Cellectar Biosciences Inc (CLRB) reported a decrease in cash and cash equivalents from $23.3 million at the end of 2024 to $12.6 million by the end of the third quarter of 2025.
Research and development expenses decreased due to lower costs related to the Clover Wham study, indicating a potential slowdown in ongoing research activities.
The company faces significant financial requirements, with an estimated $40 million needed for the full patient enrollment of the phase 3 confirmatory study in the US.
General and administrative expenses decreased significantly, which may reflect reduced pre-commercialization and market assessment efforts.
The initiation of the CLR 225 phase 1 trial for pancreatic cancer is pending additional financing, indicating potential delays in advancing this program.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CLRB.OQ - Cellectar Biosciences Inc
Q3 2025 Cellectar Biosciences Inc Earnings Call
Nov 13, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to the Select our Biosciences 3rd quarter 2025 earnings call. At this time, all lines are in listen-only mode.

Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Thursday, November 13th, 2025.

I would now like to turn the conference over to.

And see.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good morning and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.